Abstract

Our purpose was to evaluate the relevance of repeat laterally directed sextant prostate biopsy for detection of prostate cancer in high-risk patients. Our study included 195 men at high risk for prostate cancer (elevated prostate-specific antigen level and/or abnormal prostate detected by digital rectal examination). We consulted the patients in outpatient department of Kaunas University of Medicine Hospital during 2003-2007. We performed transrectal ultrasound-guided laterally directed sextant prostate biopsy in every patient. For the patients with benign histological findings and increased risk of prostate cancer, laterally directed sextant biopsies were repeated. Prostate cancer was detected in 30.3% of patients (59/195) on the first prostate biopsy, in 13.1% (11/84) on the second prostate biopsy, in 10.3% (4/39) on the third, and in 7.7% (1/13) on the forth biopsy. After all biopsies, prostate cancer was detected in 38.5% (75/195) of patients, and it differed significantly from the percentage of prostate cancer cases detected on the first biopsy (30.3%, P=0.04). We detected 78.7% (59/75) of all prostate cancer cases by the first laterally directed sextant prostate biopsy. The rest 21.3% (16/75) of cases we detected by repeat biopsies. The second laterally directed sextant prostate biopsy revealed additional 14.6% (n=11) of prostate cancer cases and increased the detection of prostate cancer to 93.3% (70/75). At the time of the first prostate biopsy, prostate cancer was diagnosed most frequently when patients had both risk factors: elevated prostate-specific antigen level and abnormal digital prostate examination; prostate cancer was diagnosed in 45.3% of these patients. The odds ratio to detect prostate cancer by the first biopsy in patients with elevated prostate-specific antigen level and abnormal digital prostate examination was 3.7, and odds ratio to detect prostate cancer by repeat biopsies was 4.7. Repeat ultrasound-guided laterally directed sextant prostate biopsies reveal more cases of prostate cancer as compared to the first prostate biopsy. The majority of prostate cancer cases (93.3%) are detected by the first and second laterally directed sextant prostate biopsies. After the first negative prostate biopsy, we recommend to repeat prostate biopsy in high-risk patients.

Highlights

  • Our purpose was to evaluate the relevance of repeat laterally directed sextant prostate biopsy for detection of prostate cancer in high-risk patients

  • Our study included 195 men at high risk for prostate cancer

  • Prostate cancer was detected in 30.3% of patients (59/195) on the first prostate biopsy, in 13.1% (11/84) on the second prostate biopsy, in 10.3% (4/39) on the third, and in 7.7% (1/13) on the forth biopsy

Read more

Summary

KLINIKINIAI TYRIMAI

Tiriamiesiems, kuriems pirmoji biopsija buvo neigiama, taip pat nustatyta padidėjusi prostatos vėžio rizika, kraštinės sekstantinės prostatos biopsijos buvo kartojamos. Prostatos vėžys po pirmosios kraštinės sekstantinės biopsijos histologiškai diagnozuotas 30,3 proc. Prostatos vėžys pirmosios biopsijos metu dažniausiai diagnozuotas esant abiem rizikos veiksniams (padidėjusiam PSA (>4 ng/ml) ir patologiniams pokyčiams prostatoje): vėžio diagnozė nustatyta 45,3 proc. Rezultatai Pirmoji kraštinė sekstantinė prostatos biopsija (TRUG PB1) atlikta kontroliuojant transrektiniu ultragarsu 195 pacientams, kuriems nustatytas padidėjęs prostatos specifinis antigenas (PSA > 4 ng/ml) ir (ar) apčiuopta patologinių pokyčių prostatoje. Pakartotinių kraštinių sekstantinių prostatos biopsijų reikšmė nustatant prostatos vėžį dėjęs PSA arba prostatoje apčiuopiama patologinių pokyčių, atliekamos pakartotinės kraštinės sekstantinės prostatos biopsijos. Tarp pirmąja prostatos biopsija nustatyto prostatos vėžio skaičiaus Norint nustatyti vieną prostatos vėžį pirmosios biopsijos metu, reikėjo atlikti prostatos biopsijas vidutiniškai 3,3 tiriamųjų.

Atlikta iš viso biopsijų
Nesergančių prostatos vėžiu tiriamųjų grupė
Material and methods
Results
Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call